Media coverage about NxStage Medical (NASDAQ:NXTM) has been trending somewhat positive this week, according to Accern. Accern rates the sentiment of news coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. NxStage Medical earned a coverage optimism score of 0.16 on Accern’s scale. Accern also gave news headlines about the medical device company an impact score of 47.612524875598 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Here are some of the news headlines that may have impacted Accern’s analysis:
- 275,000 Shares in NxStage Medical, Inc. (NXTM) Acquired by Tamarack Advisers LP (americanbankingnews.com)
- Recent Analysis Shows ILG, Diamond Offshore Drilling, Interactive Brokers Group, NxStage Medical, Broadridge Financial Solutions, and ServiceNow Market Influences — Renewed Outlook, Key Drivers of Growth (finance.yahoo.com)
- Senzar Asset Management LLC Buys New Stake in NxStage Medical, Inc. (NXTM) (americanbankingnews.com)
- NxStage Medical, Inc. (NXTM) Position Lifted by Koch Industries Inc. (americanbankingnews.com)
Shares of NxStage Medical (NASDAQ NXTM) opened at $24.37 on Friday. The company has a market cap of $1,596.34, a P/E ratio of -348.14 and a beta of 0.02. NxStage Medical has a 12-month low of $20.45 and a 12-month high of $30.80.
In related news, SVP Winifred L. Swan sold 3,500 shares of the company’s stock in a transaction that occurred on Tuesday, January 16th. The shares were sold at an average price of $24.88, for a total value of $87,080.00. Following the completion of the sale, the senior vice president now owns 13,770 shares in the company, valued at approximately $342,597.60. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In the last 90 days, insiders sold 10,500 shares of company stock valued at $261,485. 4.70% of the stock is owned by insiders.
NxStage Medical Company Profile
NxStage Medical, Inc is a medical technology company. The Company develops, manufactures and markets products and services for patients suffering from chronic or acute kidney failure. It operates through three segments. The System One segment includes revenues from the sale and rental of the System One and PureFlow SL dialysate preparation equipment and the sale of disposable products in the home and critical care markets.
Receive News & Ratings for NxStage Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical and related companies with MarketBeat.com's FREE daily email newsletter.